Introduction
============

The symptoms of human infections with dengue virus are often so similar to those of infection with chikungunya virus that clinical differentiation of the two types of infection is difficult. Infection with chikungunya virus, which belongs to the genus *Alphavirus* in the family Togaviridae, can cause conjunctivitis, debilitating polyarthralgia, diarrhoea, headache, fatigue, fever, myalgia, nausea, rashes and vomiting.[@R1] Infection with dengue virus, which belong to the genus *Flavivirus* in the family Flaviviridae, is also often associated with severe joint pain and can lead to dengue fever or to the potentially deadly severe dengue. *Aedes aegypti* and *Ae. albopictus* are the main vectors of both chikungunya and dengue virus.

Although the disease we now call chikungunya appears to have been initially described in the 1820s, almost simultaneously in East Africa -- the area now known as the United Republic of Tanzania -- and India, chikungunya virus was not isolated until 1952.[@R1]^--^[@R3] Human infections with this virus were reported in Bangkok, Thailand, in the 1960s and in India between 1963 and 1973.[@R4]^--^[@R6] Such infections may rapidly develop into large epidemics. In 2006 on an overseas department of France -- the island of La Réunion -- there was an epidemic where the incidence of chikungunya peaked at more than 40 000 cases per week.[@R7] By early 2013, chikungunya had been reported in Africa, Asia, Europe and parts of Oceania.[@R8]

Since both *Ae. aegypti* and *Ae. albopictus* occur in Haiti, chikungunya virus was expected to arrive in the country and to be disseminated rapidly.[@R9]^,^[@R10] In December 2013, the World Health Organization (WHO) reported the local spread of the virus in nearby Saint Martin -- another overseas department of France.[@R11] On 6 June 2014, the United States Centers for Disease Control and Prevention (CDC) reported 6318 chikungunya cases in Haiti and, by the end of 2014, transmission of chikungunya virus had been reported throughout the Caribbean basin.[@R12]^,^[@R13]

Because the symptoms and epidemiology of chikungunya and dengue fever are similar and occur against a backdrop of other infectious diseases, our objective was to identify and assess immunoglobulin G (IgG) responses to these closely related pathogens. A search, on 6 November 2015, for both "multiplex" and "chikungunya" in the titles and abstracts of the published articles listed by PubMed resulted in a list of 21 articles. Of these articles, nine described laboratory techniques based on the reverse-transcription polymerase chain reaction, two used assays based on the same reaction to identify chikungunya virus in the field[@R14]^,^[@R15] and one described an antibody-neutralization technique.[@R16] As multiplex bead assays allows the simultaneous collection of data on antibody responses to multiple antigens,[@R17]^--^[@R23] we investigated the use of such an assay to assess the IgG responses to antigens from chikungunya and dengue virus and *Plasmodium falciparum* in Haitian children. Our post-hoc testing of blood samples was primarily done to generate epidemiological data about the introduction of chikungunya virus in Haiti and was not aimed at diagnosis or case management.

Methods
=======

Study population and design
---------------------------

The study protocol was reviewed and approved by the Ethics Committee of the Hôpital Sainte Croix, Léogâne, Haiti, and the Institutional Review Boards of both the CDC, Atlanta, United States of America, and the University of Notre Dame, Notre Dame, USA.

We collected blood spot samples from a longitudinal cohort of 61 children -- all residents in the small coastal town of Ca Ira -- at three or all four of four time points: December 2011, February 2013, December 2013 and August 2014. All the blood spot samples collected before 2014 had been collected, from children who were aged 2--10 years in December 2011, for filariasis surveillance. In August 2014, specifically for our investigation of the bead assay, we collected blood from all 61 previously sampled children and from another 127 children from Ca Ira, then aged 2--10 years, who had not been sampled before. We considered the 127 children to represent a cross-sectional sample.

Prior to the collection of each blood spot sample, a local community health worker obtained the informed consent from a parent of the sampled child. To prepare each sample, 10 µl whole blood was collected from a finger-prick and transferred to one unused extension of a piece of filter paper with six circular extensions (TropBio Pty Ltd, Townsville, Australia). After collection, the blood spots were allowed to dry and then stored at −20 °C until tested.[@R18]

Antigens
--------

We used one recombinant chikungunya virus antigen -- that is, mutant A226V envelope 1 antigen (CTK Biotech, San Diego, USA) -- two dengue virus antigens -- propagated using a eukaryotic plasmid vector that expressed the premembrane/membrane and envelope proteins that self-assemble into two different non-infectious virus-like particles known as DENV-2 and DENV-3[@R24]^,^[@R25] -- and three recombinant antigens based on merozoite surface protein 1 of *P. falciparum*.[@R26]^--^[@R29] The DENV-2 virus-like particle has epitopes for antibodies to dengue virus serotypes 2 and 4 whereas the DENV-3 has epitopes for antibodies to serotypes 3 and 1.[@R30] The recombinant *P. falciparum* antigens represented a 42-kDa fragment from clone FVO, a 42-kDa fragment from clone 3D7 and a 19-kDa fragment from clone 3D7 (Zentrum für Molekulare Biologie der Universität Heidelberg, Heidelberg, Germany) that was linked with glutathione-*S*-transferase.[@R26]^--^[@R29]

Antigen coupling
----------------

1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (Calbiochem, Woburn, USA) was used to convert the carboxyl groups on carboxylated polystyrene beads (SeroMap Beads; Luminex Corporation, Austin, USA) to esters. The esters on the so-called activated beads could then react with amine groups on the antigens to form covalent amide bonds between the beads and the antigens. We coupled 12.5 million activated beads -- in phosphate-buffered saline at pH 7.2 -- with 30 µg of each dengue virus-like particle and 7.5 µg of the chikungunya virus antigen. For the malaria antigens and glutathione-*S*-transferase, we coupled 12.5 million activated beads, in 50 mmol/L 2-(*N*-morpholino) ethanesulfonic acid buffer with 0.85% (w/v) NaCl, at pH 5.0 -- with 28 µg of the 19-kDa fragment, from clone 3D7, linked to glutathione-*S*-transferase, 15 µg of the 42-kDa fragment from clone 3D7, 15 µg of the 42-kDa fragment from clone FVO, and 12 µg of glutathione-*S*-transferase. Coupling efficiency was evaluated using monoclonal antibodies and reference sera that were known to be highly reactive to the antigens.[@R31]^,^[@R32]

Blood spot elution
------------------

Each dried blood spot was eluted overnight, at 6 °C, in 500 µL of a buffer consisting of phosphate-buffered saline, at pH 7.2, containing 0.5% (w/v) bovine serum albumin, 0.5% (w/v) polyvinyl alcohol, 0.8% (w/v) polyvinylpyrrolidone, 0.5% (w/v) casein, 0.3% (w/v) Tween 20 and 0.02% (w/v) sodium azide. To adsorb any antibodies to *Escherichia coli* -- that might have reacted with *E. coli* proteins inadvertently coupled to the beads -- each elution was diluted 1:4 with the same buffer containing sufficient crude *E. coli* extract to give a final concentration of 3.0 µg extract per mL.[@R17] All serum specimens were diluted, 1:400, in the same buffer with the *E. coli* extract.

Bead assay
----------

### Procedure

The *E. coli*-treated samples were stored overnight at 6 °C and then clarified by centrifugation at 20 238 *g* for 10 minutes. All incubation steps were conducted at room temperature -- i.e. 20--22 °C -- in 96-well filter-bottom plates (Merck KGaA, Darmstadt, Germany). For each assay, a 50-µl clarified sample was added to a single well containing 1500 antigen-coupled beads from each coupled-bead classification and incubated, with gentle shaking, for 1.5 hours. The assay was then run as previously described.[@R17] Median fluorescence intensities between 1 and 32 766 were evaluated in a plate reader (Luminex Corporation, Austin, USA) equipped with Bio-Plex Manager 6.1 software (Bio-Rad, Hercules, USA). The background fluorescence -- from wells containing no primary antibody -- was subtracted from the mean of the median fluorescence intensities of duplicate wells to yield background-adjusted median fluorescence intensities. To evaluate inter-plate consistency, positive controls, diluted to yield low to moderate fluorescence intensities, were run on each plate.

### Positivity thresholds

For setting the threshold for assay positivity for the chikungunya virus antigen, we used assay results for the blood spots collected, before 2014, from the longitudinal cohort of Haitian children. For all the other thresholds, we used the bead assay to test 86 sera from adults who claimed to have never left the United States ([Table 1](#T1){ref-type="table"}). Any serum with background-adjusted fluorescence more than 3.0 standard deviations above the mean was considered to be an outlier and ignored. For each antigen, the threshold for assay positivity was set as the mean background-adjusted result plus 3.0 standard deviations for the relevant non-outliers.

###### Reference values and positivity thresholds for a multiplex bead assay based on antigens from chikungunya and dengue viruses and *Plasmodium falciparum*

  Pathogen, antigen                                      Reference sample**^a^**   Fluorescence intensity**^b^**   
  ------------------------------------------------------ ------------------------- ------------------------------- ------
  **Chikungunya virus**                                                                                            
  Envelope 1 antigen of mutant A226V                     Blood                     101 (−9 to 30 027)              640
  **Dengue virus**                                                                                                 
  DENV-2 virus-like particle                             Sera                      10 168 (−18 to 28 395)          982
  DENV-3 virus-like particle                             Sera                      15 047 (3 to 30 214)            3615
  ***Plasmodium falciparum***                                                                                      
  19-kDa fragment of MSP-1 of clone 3D7, linked to GST   Sera                      8 (−6 to 21 627)                105
  42-kDa fragment of MSP-1 of clone 3D7                  Sera                      29 (2 to 23 913)                189
  42-kDa fragment of MSP-1 of clone FVO                  Sera                      20 (0 to 20 489)                79
  **GST^c^**                                             Sera                      7 (−4 to 173)                   NA

GST: glutathione-*S*-transferase; MSP-1: merozoite surface protein 1; NA: not applicable.

^a^ The reference samples were 86 sera from adults who claimed to have never left the United States or 156 spots of blood collected from 62 Haitian children between 2011 and 2013.

^b^ Each reported intensity is the result of subtracting background fluorescence, from wells containing no primary antibody, from the mean of the median fluorescence intensities of duplicate wells.

^c^ Used as a protein-negative control.

A test blood spot was considered positive for an IgG response to *P. falciparum* if it was found positive for at least two of the three *P. falciparum* antigens we investigated. A test blood spot was considered positive for an IgG response to dengue virus if it was found positive for one or both of the virus-like particles we investigated.

### Validating assay for chikungunya antigen

We used both the bead assay and an enzyme-linked immunosorbent assay (ELISA) to test 78 sera -- i.e. 26 sera collected from Haitian adults in 1996, when chikungunya was known to be present in Cambodia but not in Haiti,[@R13] and 52 sera collected from Cambodian adults in 2012 -- for IgG that reacted with chikungunya virus antigen. The viral antigen used in the ELISA came from the brain of a suckling mouse and was captured with a monoclonal antibody.[@R33] Any IgG from a test serum that reacted with this antigen was probed with goat anti-human IgG linked to alkaline phosphatase. Colour was developed using disodium p-nitrophenyl phosphate and read at 405 nm.[@R33]

Spatial analysis
----------------

The positions of the 143 households that participated in the blood spot collection in August 2014 were mapped using a global positional system and ArcGIS software (ESRI, Redlands, USA). The same software was then used to perform a so-called hot-spot analysis of the corresponding bead assay results for three of the test antigens: chikungunya virus, the DENV-2 virus-like-particle and the 19-kDa malarial antigen linked to glutathione-*S*-transferase. For this analysis, we used a 400-m zone of indifference to reflect the mean range of an adult female *Ae. aegypti*.[@R34] To prevent association of the results with household locations, we aggregated the Z-scores for the Getis--Ord *G*~i~ statistic[@R35] and displaced the corresponding symbols from the actual locations.

Statistics
----------

We used Spearman's correlation to investigate the levels of association between the IgG responses for the test antigens. A *P*-value of less than 0.05 was considered indicative of statistical significance. Inter-plate consistency was evaluated as the percentage coefficient of variation for the diluted positive controls.

Results
=======

The positivity thresholds are summarized in [Table 1](#T1){ref-type="table"}. Inter-plate consistency was good, with the percentage coefficient of variation always less than 10.6. In the bead assay, monoclonal antibodies and sera known to be highly reactive to the antigens gave high background-adjusted fluorescence intensities, indicating antigen integrity and adequate antigen coupling.[@R31]^,^[@R32]^,^[@R36]

Validation
----------

In the capture ELISA, using chikungunya virus from a mouse, only 50 of the 78 tested sera gave interpretable results.[@R33] When the results of this assay were considered to be the so-called gold standard, the bead assay appeared to be 90% sensitive and 85% specific.

Longitudinal cohort
-------------------

### Prevalence of pathogen exposure

Within the longitudinal cohort ([Table 2](#T2){ref-type="table"}), no evidence of exposure to chikungunya virus was observed from 2011 to 2013 but 78.7% (46/61) of the samples tested in 2014 showed evidence of such exposure. The prevalence of exposure to dengue virus rose from 62.3% (38/61) in December 2011 to 79.0% (27/34) in February 2013 and then remained relatively unchanged for the remainder of the study. The corresponding prevalence of *P. falciparum* never exceeded 12% throughout the study. No exposure to any of the three pathogens investigated was evident in 4.9% (3/61) of the longitudinal cohort.

###### Percentages of blood spots from 61 Haitian children found bead-assay-positive for immunoglobulin G responses to antigens representing chikungunya and dengue viruses and *Plasmodium falciparum,* 2011--2014

  Pathogen                  No. positive (%)                           
  ------------------------- ------------------ ----------- ----------- -----------
  Chikungunya virus         0 (0)              0 (0)       0 (0)       48 (78.7)
  Dengue virus              38 (62.3)          27 (79.4)   49 (80.3)   48 (78.7)
  *Plasmodium falciparum*   7 (11.5)           1 (2.9)     5 (8.2)     4 (6.6)

### Temporal trends

The temporal trends in the background-adjusted fluorescence intensities are summarized in [Fig. 1](#F1){ref-type="fig"}. In the assays based on chikungunya virus antigen, the median intensities were low between 2011 and 2013 but rose sharply in 2014. In contrast, in the assays based on either of the dengue antigens we tested, median intensities were relatively low in 2011 and increased through 2013 but then fell slightly in 2014. In the assays based on any of the malarial antigens, median intensities remained low throughout the study period.

![Fluorescence intensities recorded in multiplex bead assays based on antigens representing chikungunya and dengue viruses and *Plasmodium falciparum,* Haiti, 2011--2014](BLT.16.173252-F1){#F1}

### Results for one child

The assay results for one child who was sampled at each of the four time points are summarized in [Fig. 2](#F2){ref-type="fig"}. This child was only found to have high IgG responses to the chikungunya virus antigen in 2014. In the bead assays based on the dengue virus-like-particles, this child was found barely to exceed the positivity threshold in December 2011, to be negative in February 2013 and then to be well over the positivity threshold in December 2013 -- demonstrating a secondary immune response to the dengue antigens. The child was never found positive in the assays for malarial antigens.

![Fluorescence intensities, for one child, recorded in multiplex bead assays based on antigens representing chikungunya and dengue viruses and *Plasmodium falciparum,* Haiti, 2011--2014](BLT.16.173252-F2){#F2}

Cross-sectional sample
----------------------

### Prevalence of pathogen exposure

Of the 127 children who each provided a single blood spot in 2014, 96 (75.6%), 77 (60.6%) and eight (6.3%) were found seropositive for chikungunya virus, dengue virus and *P. falciparum*, respectively, and 17 (13.4%) showed no evidence of exposure to any of these pathogens.

### Age-specific trends

In the assays based on dengue virus antigens, median intensities ([Fig. 3](#F3){ref-type="fig"}) and prevalence ([Fig. 4](#F4){ref-type="fig"}) increased with the age of the child. In the assays based on chikungunya virus antigen or malarial antigens, however, there was no indication that age had any effect on median intensities ([Fig. 3](#F3){ref-type="fig"}) or prevalence ([Fig. 4](#F4){ref-type="fig"}).

![Age-specific fluorescence intensities recorded in multiplex bead assays based on antigens representing chikungunya and dengue viruses and *Plasmodium falciparum*, Haiti, 2014](BLT.16.173252-F3){#F3}

![Age-specific prevalence of exposure to chikungunya and dengue viruses and *Plasmodium falciparum*, Haiti, 2014](BLT.16.173252-F4){#F4}

Correlations
------------

### Inter-pathogen

The Spearman's correlations indicated no significant cross-reactivity among our three study pathogens -- i.e. between chikungunya virus and either dengue virus (*r*^2^ \< 0.08; *P* \> 0.12) or *P. falciparum* (*r*^2^ \< −0.1; *P* \> 0.5) or between dengue virus and *P. falciparum* (*r*^2^ \< 0.09; *P* \> 0.08).

### Inter-antigen

In contrast, in terms of positivity in the bead assays, a strong correlation existed among the three malaria antigens (*r*^2^ \> 0.59; *P* \< 0.001) and between the two dengue antigens (*r*^2^ = 0.96; *P* \< 0.001).

Spatial analysis
----------------

Clusters identified in the spatial analysis of the study area, which lies immediately outside urban Léogâne, are shown in [Fig. 5](#F5){ref-type="fig"} (available at: <http://www.who.int/bulletin/volumes/94/11/16-173252>). In general, the detected IgG responses to the chikungunya virus antigen and DENV-2 virus-like particle appeared to get weaker the further north-west the sampling site -- i.e. the further away from the city of Léogâne and the closer to the ocean. Conversely, the corresponding responses to the 19-kDa malarial antigen linked to glutathione-*S*-transferase exhibited no discernible spatial pattern -- although they were, in general, relatively weak.

![Spatial analysis of fluorescence intensities recorded in multiplex bead assays based on antigens representing chikungunya and dengue viruses and *Plasmodium falciparum,* Haiti, 2014](BLT.16.173252-F5){#F5}

Discussion
==========

The results from the bead assay indicate that infection with chikungunya virus only became common in Haiti in 2014 and that there was rapid transmission of the virus after its introduction into an immunologically naive Haitian population. By the first week of 2015, there were 64 695 suspected cases of chikungunya virus infection in Haiti and -- since there were over 500 000 cases reported, at the same time, in the neighbouring Dominican Republic -- even this high number is likely to have been an underestimate because of underreporting.[@R13] A nationwide household survey conducted by the Igarapé Institute indicated that 9.2% of Haitians had been infected with the virus by May 2014 -- meaning there had been almost one million cases of infection within a month of the introduction of the virus into Haiti.[@R37] Such an explosive outbreak was also indicated by our bead assay results, which indicated that the prevalence of exposure to chikungunya virus among children in the town of Ca Ira increased from 0% (0/61) in 2013 to 76.6% -- i.e. 144 of the 188 children in the combined longitudinal cohort and cross-sectional sample -- in 2014.

Our bead assay was sensitive enough to show both an initial immune response and an anamnestic response to the DENV-2 and DENV-3 virus-like-particles and it appeared to be unaffected by cross-reactivity among the three pathogens we investigated. It also indicated an increasing gradient, in the level of IgG responses to chikungunya virus and dengue virus antigens, running from an urban area towards the beach. One reason for this gradient may be the preference of *Ae. aegypti* and *Ae. albopictus* for habitats with relatively lower salinity and/or wind activity.[@R38] The relatively high density of the human population in the more urban areas we investigated may also favour transmission.

Our results relating to dengue virus were consistent with those of previous studies on dengue in Haiti. Prior to 1969, dengue virus had not been reported in Haiti. In a study conducted in Port-au-Prince between 1969 and 1971, however, antibody responses to this pathogen were detected in 43%, 60% and 76% of the subjects aged 1--5, 6--10 and 41--50 years, respectively.[@R9] In 1996, in a later study in Port-au-Prince, 85% of the children aged 6--13 years who were screened with a neutralizing antibody test were found positive for at least one dengue virus serotype.[@R39]

Our results relating to chikungunya virus, although based on a relatively small sample, are consistent with those of an unpublished but much larger study conducted in early 2015. The subjects of this larger study, which was focused on malaria, were checked for IgG responses to the chikungunya virus we used in the bead assay. The seroprevalence of such responses was found to be 82% in urban areas throughout Haiti -- similar to the 79% found in our urban study site -- and only 45% in rural areas (Eric Rogier, CDC, Atlanta, USA, personal communication, February 2016). In Haiti, rural areas are generally at higher altitudes than urban areas and the cool temperatures at high altitudes tend to limit vector densities.

Multiplex bead assays have been found to be at least as sensitive as ELISA[@R40]^--^[@R42] and are relatively efficient since they require only 125 nL of specimen per well, in a 96-well format, while accommodating up to 100 antigens or data points per well. They can deliver efficiencies of cost, sample and labour while providing the opportunity to monitor the prevalence of exposure to multiple pathogens simultaneously. By analysing fluctuations in IgG responses to several antigens over time, with multiple blood samples from the same individual, such assays could also define exposure histories. Given the confirmed autochthonous transmission of Zika virus in Haiti and across the Americas,[@R20]^,^[@R43] exposure histories are urgently needed. At a time when funding for the surveillance of a single disease is becoming increasingly difficult to defend, the versatility offered by multiplex bead assays could permit the longitudinal and cost--effective monitoring of multiple pathogens within a single study.
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Patents issued in Australia (2,005,200,365), Canada (2,495,138 and 2,775,655) and the USA (7,933,721 B2 and 8,433,523 B2) to AJB and BJB describe microsphere assays that may be used to detect antibodies to arboviruses such as the chikungunya and dengue viruses.
